Evidence map›Paper›PMID 37402031›Full record

ReviewDermatology and therapy2023

Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies.

Natalie M Fragoso, Rahul Masson, T Justin Gillenwater, Vivian Y Shi, Jennifer L Hsiao

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Dermatology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Natalie M FragosoDepartment of Dermatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.
Rahul MassonKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
T Justin GillenwaterDivision of Plastic and Reconstructive Surgery, University of Southern California, Los Angeles, CA, USA.
Vivian Y ShiDepartment of Dermatology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Jennifer L HsiaoDepartment of Dermatology, University of Southern California, 1441 Eastlake Ave, Ezralow Tower, Suite 5301, Los Angeles, CA, 90089, USA. j.hsiao.publications@gmail.com.
University of Southern California · USDartmouth–Hitchcock Medical Center · USUniversity of Arkansas for Medical Sciences · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hidradenitis suppurativa (HS) is an oftentimes debilitating condition that presents with painful nodules, abscesses, and sinus tracts. This condition is challenging to treat, in part because the pathogenesis of the condition is incompletely understood but also because there are limited therapeutic options. HS research is undergoing explosive growth with multiple new molecular pathways under study, which will hopefully lead to improved disease control for patients. Part I of this review will provide an overview of the emerging topical and systemic therapies under investigation for HS.

Indexed as

Clinical trialsHidradenitis suppurativaSystemicTopicalTreatment

Identifiers

PMID37402031
PMCPMC10366071
OpenAlexW4383058424

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.